Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$5.85M$5.85Mderived−30.8% vs Q4 2021 Net Income-$8.10M-$8.10MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$11,519,000N/M Operating Cash Flowderived-$12,933,000N/M Free Cash Flowderived-$12,922,000N/M Margins · derivedOperating margin-197.0%−66.8 pt vs Q4 2021
Net margin-138.6%−25.7 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 31, 2023 · 90 d after period end